HRAS and urinary bladder carcinoma: To study the role of the HRAS cancer target and cisplatin resistance in bladder cancer, a T24 cell line with mutant HRAS (G12V, ATCC), expressing the highest level of HRAS (Figure 1D), and displaying the best sensitivity to pterostilbene was chosen for further experiments.